Message Font: Serif | Sans-Serif
No. of Recommendations: 2
Biogen Falls From the A-List to Listing Badly

This seems like potentially good news for DNA. previously examined the somewhat disappointing Amevive results released two weeks ago at a psoriasis research conference. The miscue is exacerbated by the fact that Amevive has serious competition from another experimental psoriasis drug under development by Genentech (DNA:NYSE) and Xoma (XOMA:NYSE). That drug, Xanelim, looked more impressive at the conference.

Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.